<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
    <effectiveTime value="20200616"/>
   <setId root="77c4b13e-7df3-42d4-81db-3d0cddb7f67a"/>
   <versionNumber value="9"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="002147023" root="1.3.6.1.4.1.519.1"/>
            <name>Novartis Pharmaceuticals Corporation</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="4621ff52-dd3b-4de5-a469-570793d807c0"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="59845-8" displayName="NAME OF THE MEDICINAL PRODUCT"/>
               <title/>
               <text>
                  <paragraph>
                  #Updated SMPC at Batch level# Cosentyx 150 mg powder for solution for injection
                  </paragraph>
                 
               </text>
            </section>
        </component>
		<component>
            <section>
               <id root="4621ff52-dd3b-4de5-a469-570793d807c0"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="59845-8" displayName="QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
               <title/>
               <text>
                  <paragraph>
                   Each vial of powder contains 150 mg secukinumab. After reconstitution, 1 ml of solution contains 150 mg secukinumab.
                  </paragraph>
                 <paragraph>
				Secukinumab is a recombinant fully human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells.
				 </paragraph>
				 <paragraph>
				 For the full list of excipients, see section 6.1.
				 </paragraph>
               </text>
            </section>
         </component>
		 <component>
            <section>
               <id root="4621ff52-dd3b-4de5-a469-570793d807c0"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="59845-8" displayName="PHARMACEUTICAL FORM"/>
               <title/>
               <text>
                  <paragraph>
                   Powder for solution for injection
                  </paragraph>
                 <paragraph>
				The powder is a white solid lyophilisate.
				 </paragraph>
               </text>
            </section>
         </component>
		 <component>
            <section>
               <id root="4621ff52-dd3b-4de5-a469-570793d807c0"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="59845-8" displayName="DATE OF REVISION OF THE TEXT"/>
               <title/>
               <text>
                  <paragraph>
                   Detailed information on this medicinal product is available on the website of the European Medicines Agency <linkHtml href="http://www.ema.europa.eu">http://www.ema.europa.eu</linkHtml>.
                  </paragraph>
                 
               </text>
            </section>
        </component>
      </structuredBody>
   </component>
</document>